Issue: July 2017
June 05, 2017
1 min read
Save

OrphoMed Secures $39 Million to Develop IBS-D Treatment

Issue: July 2017
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

OrphoMed Inc. completed a $39 million Series A financing, the capital of which they will use to accelerate clinical development of its lead candidate, ORP-101, a peripherally acting dimer, for the treatment of irritable bowel syndrome with diarrhea, according to a press release.

“There are only a couple of drugs approved for the treatment of IBS-D, each with its own specific limitations, either regarding safety or efficacy,” Kenneth Widder, MD, OrphoMed’s executive chairman, said in the release. “There still are a significant number of patients who cannot be treated with existing approved drugs. As such, we feel there is a large opportunity to bring forward a drug which circumvents the limitations of those drugs currently on the market.”

The Series A financing round, led by New Enterprise Associates (NEA), will allow the company to advance development of this potential treatment of IBS-D. ORP-101, a metabolically stable, partial agonist of the mu opioid receptor and antagonist of the kappa opioid receptor, alleviates abdominal pain due to intestinal hyperalgesia and gastric hypermotility associated with IBS-D without CNS penetration. Prior study in animal models has shown that ORP-101 consistently suppresses general and colon-specific hyperalgesic signals without causing constriction of the sphincter of Oddi, which can occur with other mu agonists.

“This is an exciting opportunity driven by a lead candidate with a proven mechanism of action, a large underserved patient population, and a results-oriented team with recent drug development success,” Frank Torti, MD, partner at NEA said. “We are thrilled to partner with the OrphoMed team as they work to bring ORP-101 to patients in need.”

Disclosures: Widder is an executive chairman at OrphoMed. Torti is a partner at New Enterprise Associates.